NO976122D0 - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents
AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendesInfo
- Publication number
- NO976122D0 NO976122D0 NO976122A NO976122A NO976122D0 NO 976122 D0 NO976122 D0 NO 976122D0 NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 D0 NO976122 D0 NO 976122D0
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- fas ligand
- fas
- apoptosis
- assay method
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 10
- 238000003556 assay Methods 0.000 title abstract 5
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 5
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 5
- 230000006907 apoptotic process Effects 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 210000001124 body fluid Anatomy 0.000 abstract 2
- 239000010839 body fluid Substances 0.000 abstract 2
- 108010052621 fas Receptor Proteins 0.000 abstract 2
- 102000018823 fas Receptor Human genes 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18848095 | 1995-06-30 | ||
| US08/649,100 US6114507A (en) | 1995-06-30 | 1996-05-17 | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| PCT/JP1996/001820 WO1997002290A1 (en) | 1995-06-30 | 1996-07-01 | ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO976122D0 true NO976122D0 (no) | 1997-12-29 |
| NO976122L NO976122L (no) | 1998-02-27 |
| NO324120B1 NO324120B1 (no) | 2007-08-27 |
Family
ID=26504954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19976122A NO324120B1 (no) | 1995-06-30 | 1997-12-29 | Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0842948B1 (no) |
| JP (1) | JP3925663B2 (no) |
| CN (1) | CN1196733A (no) |
| AU (1) | AU724856B2 (no) |
| CA (1) | CA2225852C (no) |
| NO (1) | NO324120B1 (no) |
| NZ (1) | NZ311174A (no) |
| WO (1) | WO1997002290A1 (no) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010070A1 (en) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND |
| US5858990A (en) * | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| CA2309598A1 (en) | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
| EP1059089B1 (en) * | 1998-02-06 | 2007-03-28 | Mochida Pharmaceutical Co., Ltd. | Preventives/remedies for inflammatory intestinal disease |
| WO1999058150A1 (en) * | 1998-05-14 | 1999-11-18 | Mochida Pharmaceutical Co., Ltd. | Preventives/remedies for hepatic cirrhosis |
| ATE333287T1 (de) * | 1998-05-29 | 2006-08-15 | Mochida Pharm Co Ltd | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP4734739B2 (ja) * | 2000-09-29 | 2011-07-27 | 東レ株式会社 | 哺乳動物のガン抑制方法 |
| EP1490405B1 (en) * | 2002-03-21 | 2007-08-22 | Eli Lilly And Company | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
| WO2003086458A1 (en) * | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
| TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| BRPI0317376B8 (pt) * | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica |
| EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| EP2316487B1 (en) * | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | 標的化された炎症惹起剤 |
| US9309320B2 (en) | 2006-12-28 | 2016-04-12 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
| HRP20150457T1 (hr) * | 2007-12-12 | 2015-06-05 | Pincell Srl | Lijekovi protiv pemfigusa koji sadrže anti-fas lagand antitijela |
| US8540987B2 (en) | 2008-01-29 | 2013-09-24 | Institute For Antibodies Co., Ltd. | Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody |
| PT2376536E (pt) | 2008-12-12 | 2015-05-11 | Pincell Srl | Remédios para pênfigo contendo anticorpos anti-ligando de faz |
| JP5754740B2 (ja) * | 2009-07-21 | 2015-07-29 | クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ | 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| DK3140653T3 (da) | 2014-05-08 | 2022-06-20 | Novodiax Inc | Direkte immunhistokemianalyse |
| EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
| AU2016325482B2 (en) * | 2015-09-23 | 2020-09-03 | Apogenix Ag | Anti-CD95L antibody |
| PL3592392T3 (pl) * | 2017-03-10 | 2024-03-18 | University Of Louisville Research Foundation, Inc. | Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej |
| WO2023138521A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| US20250257141A1 (en) | 2022-04-26 | 2025-08-14 | Hoffmann-La Roche Inc. | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU705114B2 (en) * | 1993-10-14 | 1999-05-13 | Immunex Corporation | Fas antagonists and uses thereof |
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| AU705484B2 (en) * | 1994-01-07 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| EP0872488B1 (en) | 1995-03-20 | 2006-05-24 | Ko Okumura | MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME |
-
1996
- 1996-07-01 CN CN96196690A patent/CN1196733A/zh active Pending
- 1996-07-01 EP EP96921136A patent/EP0842948B1/en not_active Expired - Lifetime
- 1996-07-01 WO PCT/JP1996/001820 patent/WO1997002290A1/ja not_active Ceased
- 1996-07-01 JP JP50498997A patent/JP3925663B2/ja not_active Expired - Fee Related
- 1996-07-01 CA CA002225852A patent/CA2225852C/en not_active Expired - Fee Related
- 1996-07-01 AU AU62435/96A patent/AU724856B2/en not_active Ceased
- 1996-07-01 NZ NZ311174A patent/NZ311174A/en not_active IP Right Cessation
-
1997
- 1997-12-29 NO NO19976122A patent/NO324120B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1196733A (zh) | 1998-10-21 |
| NZ311174A (en) | 1999-04-29 |
| WO1997002290A1 (en) | 1997-01-23 |
| EP0842948A4 (en) | 2004-12-15 |
| EP0842948A1 (en) | 1998-05-20 |
| NO324120B1 (no) | 2007-08-27 |
| AU724856B2 (en) | 2000-10-05 |
| JP3925663B2 (ja) | 2007-06-06 |
| AU6243596A (en) | 1997-02-05 |
| CA2225852C (en) | 2009-04-14 |
| NO976122L (no) | 1998-02-27 |
| EP0842948B1 (en) | 2009-04-22 |
| CA2225852A1 (en) | 1997-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO976122D0 (no) | AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes | |
| Anderson et al. | Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes. Antibody characterization and induction of superoxide production in a monocyte cell line. | |
| Schuurman et al. | Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites | |
| ATE165866T1 (de) | Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung | |
| Morell et al. | Human IgG subclasses in maternal and fetal serum | |
| DE69322860D1 (de) | Antikörper gegen alpha v beta 3 integrin | |
| PT699237E (pt) | Fvs de cadeia anti-egfr e anticorpos anti-egfr | |
| DE69637909D1 (de) | ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN | |
| RU94045826A (ru) | Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i | |
| FI964845A0 (fi) | CD44v6:n vastaiset monoklonaaliset vasta-aineet | |
| EP0552296A4 (en) | Mouse monoclonal antibodies | |
| KR960010024A (ko) | 류머티즘 치료제 | |
| SE8300320D0 (sv) | Monoclonal antibody formulation for diagnostic use | |
| DE69431526T2 (de) | Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26 | |
| GR3025630T3 (en) | Monoclonal antibody against human IgE | |
| ID25978A (id) | Antibodi anti-fas | |
| Yu et al. | A monoclonal antibody with anti‐D–like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects | |
| FR2560212B1 (fr) | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps | |
| Ezzatifar et al. | Large scale generation and characterization of anti-human IgA monoclonal antibody in ascitic fluid of BALB/c mice | |
| BG96346A (bg) | Специфични свързващи вещества | |
| DE2853453C2 (no) | ||
| JP2019513346A (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| NO981454D0 (no) | Anti-FAS-antistoffer | |
| Litwin et al. | Genetic factors of human gamma globulin detected by rabbit antisera | |
| ATE77243T1 (de) | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. |